BC
NVLN

Bartlett & Co’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Bartlett & Co’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-400
Closed -$1K – 769
2017
Q4 		$1K Hold
400
– – ﹤0.01% 686
2017
Q3 		$3K Buy
+400
New +$3.21K ﹤0.01% 646

Other funds holding NVLN

EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Bartlett & Co's NVLN Position: Q1 2018 in Review

Bartlett & Co sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q1 2018, closing a stake of 400 shares — an estimated $1K sold.

Bartlett & Co first reported a position in NVLN in Q3 2017 and held it in 2 quarters. The position peaked at $3K in Q3 2017. 68 funds tracked by Wall St. Rank hold NVLN as of Q1 2018.

  • Bartlett & Co reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q1 2018 after selling out during the quarter.
  • Bartlett & Co sold 400 Novelion Therapeutics Inc. Common Shares shares in Q1 2018, an estimated $1K.
  • Bartlett & Co first reported a position in Novelion Therapeutics Inc. Common Shares in Q3 2017 and held it in 2 quarters.
  • Bartlett & Co's Novelion Therapeutics Inc. Common Shares position peaked at $3K in Q3 2017.
  • 68 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q1 2018.

Based on Bartlett & Co's 13F filing for Q1 2018, filed 25 Apr 2018.